Guest guest Posted December 26, 2010 Report Posted December 26, 2010 OFFICIAL CONFERENCE COVERAGE 2010 Annual Meeting of the American Association for the Study of Liver Diseases CCO is the official provider of online Conference Coverage of The Liver Meeting® 2010. To: CCO member From: Norah Terrault, MD, MPH University of California, San Francisco San Francisco, California Subject: CME-Certified Expert Analysis From AASLD 2010 Click to Access: Updates in HBV Treatment While attending the Annual AASLD meeting in Boston, I met with S. F. Lok, MD, and Marcellin, MD, to review some of the most noteworthy new data on HBV treatment. Our discussion is now available on the Clinical Care Options Web site as a CME-certified Expert Analysis. Select topics include: Study 103: 4 Years of Tenofovir in Patients With HBeAg-Positive Chronic HBV Infection Study 102: 4 Years of Tenofovir in Patients With HBeAg-Negative Chronic HBV Infection Prevalence of Proximal Tubular Dysfunction During Tenofovir Therapy for Chronic HBV Infection NEPTUNE: Peginterferon alfa-2a 90 µg/week vs 180 µg/week for 24 vs 48 Weeks in Patients With HBeAg-Positive HBV Infection PegBeLiver: Peginterferon alfa-2a for 48 vs 96 Weeks in Patients With HBeAg-Negative Genotype D HBV Peginterferon alfa-2b for 24 vs 48 Weeks in Patients With HBeAg-Positive HBV Infection Impact of Mode of Delivery on Perinatal HBV Transmission Risk Telbivudine Treatment During Late Pregnancy for Prevention of Perinatal HBV Transmission Incidence and Correlates of Liver Outcomes Among Patients With Chronic HBV Infection To review this CME-certified Expert Analysis, click here. This Expert Analysis is located online at: http://clinicaloptions.com/Hepatitis/Conference%20Coverage/AASLD%202010.aspx Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. Release date: December 17, 2010 Expiration date: December 16, 2011 Supported by educational grants from Bristol-Myers Squibb, Janssen Pharmaceutical Companies of & , Merck, and Vertex. PARTNERSHIP INFORMATION CCO is the official provider of online conference coverage of The Liver Meeting® 2010. For more information about the AASLD, go to http://www.aasld.org. Clinical Care Options Hepatitis GET MORE FROM CCO Hepatitis Slide Library Review hundreds of slidesets featuring the latest data on hepatitis management. Then download PowerPoint files for use in your own noncommercial talks. Click here to start. Conference Coverage Journal Options Management Series Treatment Updates Interactive Cases Live Meetings RSS / Podcasts My CME Tracker Free Bookstore Slide Downloads Copyright 2010 Clinical Care Options, LLC. All rights reserved. 1894 Preston White Drive, Suite 110, Reston, VA 20191-5433 To ensure you receive Clinical Care Options educational materials by email, please add info@... to your contacts or address book. Not a member yet? Click here | Unsubscribe from all emails sent from CCO | Manage email preferences Quote
Guest guest Posted December 26, 2010 Report Posted December 26, 2010 OFFICIAL CONFERENCE COVERAGE 2010 Annual Meeting of the American Association for the Study of Liver Diseases CCO is the official provider of online Conference Coverage of The Liver Meeting® 2010. To: CCO member From: Norah Terrault, MD, MPH University of California, San Francisco San Francisco, California Subject: CME-Certified Expert Analysis From AASLD 2010 Click to Access: Updates in HBV Treatment While attending the Annual AASLD meeting in Boston, I met with S. F. Lok, MD, and Marcellin, MD, to review some of the most noteworthy new data on HBV treatment. Our discussion is now available on the Clinical Care Options Web site as a CME-certified Expert Analysis. Select topics include: Study 103: 4 Years of Tenofovir in Patients With HBeAg-Positive Chronic HBV Infection Study 102: 4 Years of Tenofovir in Patients With HBeAg-Negative Chronic HBV Infection Prevalence of Proximal Tubular Dysfunction During Tenofovir Therapy for Chronic HBV Infection NEPTUNE: Peginterferon alfa-2a 90 µg/week vs 180 µg/week for 24 vs 48 Weeks in Patients With HBeAg-Positive HBV Infection PegBeLiver: Peginterferon alfa-2a for 48 vs 96 Weeks in Patients With HBeAg-Negative Genotype D HBV Peginterferon alfa-2b for 24 vs 48 Weeks in Patients With HBeAg-Positive HBV Infection Impact of Mode of Delivery on Perinatal HBV Transmission Risk Telbivudine Treatment During Late Pregnancy for Prevention of Perinatal HBV Transmission Incidence and Correlates of Liver Outcomes Among Patients With Chronic HBV Infection To review this CME-certified Expert Analysis, click here. This Expert Analysis is located online at: http://clinicaloptions.com/Hepatitis/Conference%20Coverage/AASLD%202010.aspx Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. Release date: December 17, 2010 Expiration date: December 16, 2011 Supported by educational grants from Bristol-Myers Squibb, Janssen Pharmaceutical Companies of & , Merck, and Vertex. PARTNERSHIP INFORMATION CCO is the official provider of online conference coverage of The Liver Meeting® 2010. For more information about the AASLD, go to http://www.aasld.org. Clinical Care Options Hepatitis GET MORE FROM CCO Hepatitis Slide Library Review hundreds of slidesets featuring the latest data on hepatitis management. Then download PowerPoint files for use in your own noncommercial talks. Click here to start. Conference Coverage Journal Options Management Series Treatment Updates Interactive Cases Live Meetings RSS / Podcasts My CME Tracker Free Bookstore Slide Downloads Copyright 2010 Clinical Care Options, LLC. All rights reserved. 1894 Preston White Drive, Suite 110, Reston, VA 20191-5433 To ensure you receive Clinical Care Options educational materials by email, please add info@... to your contacts or address book. Not a member yet? Click here | Unsubscribe from all emails sent from CCO | Manage email preferences Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.